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1. Introduction
Oligomerization of amino acids by binding their peptide bonds (-CONH-) forms proteins (or
peptides), which are the major components of our bodies. Although the primary sequence (the
linear sequence of amino acids) of the protein mainly determines its characteristics, its
secondary structures (the conformations) are also critical determinants of their shapes and
functions. The conformation (random coil, α-helix, and ß-sheet) is restricted by the circum‐
stances nearby proteins. The hydrogen bond between the amino acids in the peptide chain
forms the α-helix structure. Meanwhile, the ß-sheets (ß-plated sheets) consist of ß-strands
which are laterally connected peptide bonds with hydrogen bonds.
Recent neurochemical evidence indicates that the oligomerization of proteins and the forma‐
tion of ß-sheet structures are linked with several neurodegenerative diseases such as Alz‐
heimer’s disease (AD), prion diseases, triplet repeat diseases, dementia with Lewy bodies
(DLB). The disease-related proteins, such as ß-amyloid protein (AßP) in AD, prion protein in
prion diseases, polyglutamine in triplet repeat disease, α-synuclein in DLB, are identical in
each disease (Table 1). However, all of these amyloidogenic proteins share common charac‐
teristics in the formation of amyloid with ß-sheet structures, and in the exhibition of cytotox‐
icity. Therefore, a new concept termed “conformational disease” was proposed, suggesting
that protein conformation is an important determinant of its toxicity, and consequently, the
development of the related disease [1].
These conformational diseases are included in amyloidosis. At 1853, Virchow found the
abnormal accumulates in tissues and named “amyloid”, since they exhibited similar charac‐
teristics with amylum. At 1968, amyloid was determined to be the oligomers of proteins with
ß-sheet structures. The accumulation of amyloid causes various diseases (amyloidosis)
including familial amyloid polyneuropathy (FAP), amyloid-light chain amyloidosis, dialysis
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amyloidosis, etc [2]. All of theses diseases share common properties about the deposition of
amyloids in various tissues or organs with protease-resistant, insoluble fibril-like structures
(amyloid fibrils), and stained by congo-red, ß-sheet specific dye. However, the component of
amyloid is different in each disease. For example, the major component of amyloid in FAP
patients is transthyretin, and ß2-microglobulin deposits in patients with dialysis amyloidosis.
There are no effective treatments for amyloidosis.
In this chapter, we review the implication of protein oligomerization in the pathogenesis of
these neurodegenerative diseases. Considering that the amyloidogenic proteins are commonly
present in our brain, factors which influence oligomerization play crucial roles in their
pathogenesis. As such factors, we focus on trace elements such as Al, Zn, Cu, and Fe. Metals
have a property of firmly binding to metal-binding residues of proteins, such as tyrosine (Tyr)
Disease The primary sequence of amyloidogenic protein
or its fragment peptide
Metal ß-sheet
formation
Cyto-
toxicity
Pore-
formation
Alzheimer’s
disease
AßP(1-42) and AßP(1-42)truncated C-terminal
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG
VVIA
Al, Zn, Cu,
Fe
+ + +
Prion disease Prion protein: PrP106-126
MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGG
SRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPH
GGGWGQPHGGGWGQPHGGGWGQGGGTHSQWN
KPSKPKTNMKHMAGAAAAGAVVGGLGGYVLGSAMS
RPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQ
NNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVV
EQMCITQYERESQAYYQRGSSMVLFSSPPVILLISFLIFL
IVG
Zn, Cu,
M,
Fe
+ + +
Dementia with
Lewy bodies
(DLB)
α-synuclein; NAC ( a fragment of α-synuclein )
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEG
VLYVGSKTKEGVVHGVTTVAEKTKEQVSNVGGAVVTG
VTAVAHKTVEGAGNFAAATGLVKKDQKNESGFGPEG
TMENSENMPVNPNNETYEMPPEEEYQDYDPEA
Cu, Fe,
Al
+ + +
Triplet- repeat
disease
Polyglutamine
MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQ
QQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPP
PPPPPPGP
Fe + + +
Diabetes mellitusHuman amylin
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY
Cu, Al + + +
* The sequence of fragment peptide of each amyloidogenic protein (PrP106-126, NAC, polyglutamine) is indicated in
italic form.
Table 1. Characteristics of amyloidogenic proteins and the related peptides
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or histidine (His) or phosphorylated amino acids, and cause cross-linking of the proteins (Fig.
1). Furthermore, all of these amyloidogenic proteins were reported to have the ability to bind
metals as shown in Table 1. Our and other numerous studies reported that oligomers cause
neurodegeneration by induction of Ca2+ dyshomeostasis through the formation of amyloid
channels on neuronal membranes [3,4]. The beneficial characteristics of carnosine (ß alanyl
histidine) as a drug for the treatment for these neurodegenerative diseases are also discussed.
M
HisTyr Arg
Phosphorylated
amino acid
M
M
M
M
M
Amyloidogenic protein Oligomers with ß-sheet structures
M stands for metal.
Figure 1. Trace elements acts cross-linkers of amyloidogenic proteins.
2. Alzheimer’s disease and oligomerization of AßP
2.1. Amyloid cascade hypothesis
Alzheimer’s disease (AD) is a severe type of senile dementia, affecting a large portion of elderly
people worldwide. It is characterized by profound memory loss and inability to form new
memories. The pathological hallmarks of AD are the presence of numerous extracellular
deposits (senile plaques) and intraneuronal neurofibrillary tangles (NFTs). The degeneration
of synapses and neurons in the hippocampus or cerebral cortex is also observed. The major
components of NFTs are phosphorylated tau proteins, and that of senile plaques are ß-amyloid
proteins (AßPs) [5]. Although the precise cause of AD remains elusive, numerous biochemical,
cell biological, and genetic studies have supported the idea termed “amyloid cascade hypoth‐
esis” that the AßP accumulation and the consequent neurodegeneration play a central role in
AD [6]. Moreover, recent studies on the identified AßP species have indicated that the
oligomerization of AßP and the conformational changes are critical in the neurodegeneration
process [7].
AßP is a small peptide of 39–43 amino acid long. It is derived from the proteolytic cleavage of
a large precursor protein (amyloid precursor protein; APP). AßP is secreted by the cleavage
of its N-terminal by ß-secretase (BACE), followed by the intra-membrane cleavage of its C-
terminal by γ-secretase. Genetic studies of early-onset cases of familial AD indicated that APP
mutations and AßP metabolism are associated with AD. It was also revealed that mutations
Oligomerization of Proteins and Neurodegenerative Diseases
http://dx.doi.org/10.5772/57482
281
in the presenilin genes account for the majority of cases of early-onset familial AD. Presenilins
have been revealed to be one of γ -secretases, and their mutations also influence the production
of AßP and its neurotoxicity.
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKK-Primate AßP: 
APP 
membrane
DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVVIATRodent AßP:
ß-secretase -secretase
AßP is secreted from its precursor protein, APP by transmembrane cleavage. Sequences of primate AßP(1-42) and ro‐
dent AßP(1-42) are shown. The comparison between the sequence of primate (human or monkey) Aß(1-42) and ro‐
dent (rat or mouse) Aß(1-42) is depicted.
Figure 2. Structure of AßP
Yankner et al. reported that the first 40 amino acid residues of AßP (AßP(1–40)) caused the
death of cultured rat hippocampal neurons or the neurodegeneration in the brains of experi‐
mental animals. Thereafter, it was agreed upon that the aggregation and the subsequent
conformational change of AßP contribute to its neurotoxicity. AßP is a hydrophobic peptide
with an intrinsic tendency to self-assemble to form insoluble oligomers with ß-pleated sheet
structures. Pike et al. revealed that aged AßP(1–40) (aggregated under incubation at 37°C for
several days) were considerably more toxic to cultured neurons as compared to freshly
prepared AßP(1–40). Simmons et al. revealed ß-sheet contents of AßP observed by circular
dichroism (CD) spectroscopy correlates with its neurotoxicity.
Furthermore, the longer peptide variant, AßP(1–42), has the characteristics of immediate
polymerization compared to AßP(1–40). AßP(1–42) enhances the aggregation of AßP(1–40)
and becomes a seed of the amyloid fibrils. AßP (1–42) is more abundant in the brains of AD
patients as compared to those of age matched controls. The mutations of APP and those of
presenilin genes induce the increased production of AßP (1–42) in the transfected cell lines.
Recent approaches using size-exclusion chromatography, gel electrophoresis, and atomic force
microscopy have demonstrated that there are several stable types of soluble oligomers:
naturally occurring soluble oligomers (dimers or trimers), ADDLs (AßP-derived diffusible
ligands), AßP globulomers, or protofibrils. Hartley separated aggregated AßP(1–40) into low–
molecular-weight (mainly monomer), protofibrillar, and fibril fractions by size-exclusion
chromatography, and found that the protofibrillar fraction caused marked changes in the
electrical activity of cultured neurons and neurotoxicity. Walsh et al. found that the intracere‐
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bral administration of the conditioned medium with cultured cells transfected with the human
APP gene inhibited long-term potentiation (LTP), which is a form of synaptic information
storage well known as a paradigm of memory mechanisms. They also demonstrated that LTP
was blocked by SDS-stable low-molecular-weight oligomers (dimers, trimers, or tetramers)
but not AßP monomers or larger aggregates. The natural AßP oligomers (derived from the
cerebrospinal fluid of AD patients) cause the loss of dendritic spines, synapses, and LTP
blockage. Klein and the colleagues reported that AßP-derived diffusible ligands (ADDLs)
obtained from sedimentation by clustering are highly toxic to cultured neurons. They also
reported that ADDLs inhibited LTP and exhibited adverse effects on synaptic plasticity such
as abnormal spine morphology, decreased spine density, and decreased synaptic proteins.
Based on these and other numerous findings, it is widely accepted that AßP oligomers are
synaptotoxic and neurotoxic, but not monomer or fibrils. These studies further strengthened
and modified the amyloid cascade hypothesis, which suggest that AßP oligomers are neuro‐
toxic and crucial for the pathogeneis of AD [8,9].
2.2. Metal-induced oligomerization of AßP
Considering that AßP is secreted from APP into the brain of young people or of normal
subjects, factors which influence (accelerate or delay) the oligomerization may become
important determinants of the pathogenesis of AD. Various factors, such as the concentration
of peptides, the oxidations, mutations, and racemization of AßP, pH, composition of solvents,
temperature, and trace elements, can influence the oligomerization processes. A considerable
amount of asparagines (Asp) or serine (Ser) residues of AßP accumulated in senile plaques are
• ß-sheet
• insoluble
• less or non-toxic
• aging (incubation) 
• metals (Al, Cu, Zn, etc.)
• oxidation
• Mutation
• racemization etc.
• rifampicin
• curcumine
• polyphenol
• aspirin
• ß-sheet breaker peptide etc.
monomer Soluble oligomer Amyloid fibril
AßP 
• -helix
or randam coil
• soluble
• non-toxic
• ß-sheet
• soluble
• toxic
Acceleratory factors
Inhibitory factors
protofibril
ADDLs
globulomer etc.
Toxicity
AßP monomers exhibit random or a-helix structures. However, under aging conditions or in the presence of some ac‐
celeratory factors, Aß self-aggregates and forms several types of oligomers (SDS-soluble oligomers, ADDLS, globulom‐
ers, or protofibrils etc.) and finally forms insoluble aggregates termed amyloid fibrils. Oligomeric soluble Aßs are toxic,
although the monomeric and fibril ones are rather nontoxic.
Figure 3. Oligomerization of AßP
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racemized. Tomiyama et al. reported that racemized D-Asp23-AßP easily aggregates compared
to the L-type. Meanwhile, several substances such as rifampicin, curcumin, and aspirin have
been reported to inhibit AßP oligomerization in vitro. Rifampicin, a drug used to treat Hansen’s
disease, may be an interesting inhibitor of oligomerization since patients with Hansen’s disease
have a low susceptibility to AD. Aspirin and other NSAIDs (non-steroidal anti-inflammatory
drugs) inhibit the AßP oligomerization and simultaneously attenuate inflammation.
Among these factors, trace elements such as aluminum (Al), zinc (Zn), copper (Cu), iron (Fe)
are of particular interest. The accumulation of AßP is rarely observed in the brains of rodents
(rats or mice) as compared to humans or monkeys. As shown in Fig.2, the amino acid sequence
of human and rodent AßP are similar, yet they differ by three amino acids. However, rodent
AßP exhibits less tendency to oligomerization compared to human AßP [10]. Considering that
these three amino acids (Arg5, Tyr10, and His13) have the ability to bind metals and that trace
metals have cross-linking ability, trace elements might play important roles in the accumula‐
tion of AßP in the human brain.
Exley et al. first demonstrated that Al induces a conformational change in AßP(1-40) by CD
spectroscopy. Furthermore, exposure to Al causes the accumulation of AßP in cultured
neurons or in brains of experimental animals or human. Pratico et al. found that Al-fed mice
transfected with the human APP gene (Tg 2576) exhibited pathological changes similar to those
of the AD brain, including a marked increase in the amount of AßP both in the secreted form
and the accumulated form: an increased deposition of senile plaques was also observed [11].
The neuropathological case study of the accidental Al-exposure that occurred in 1988 at
Camelford (Cornwall, U.K.) indicated that the exposure to Al, even if it is short-term, could
cause the accumulation of AßP and exhibit severe amyloid angiopathy [12]. Since there have
been studies indicating the link between Al in drinking water and the pathogenesis of AD, Al-
induced oligomerization may directly implicated in AD pathogenesis [13].
Bush et al. demonstrated that Zn2+ and Cu2+caused the oligomerization of AβP [14]. However,
the metal-induced oligomerization of AßP and other amyloidogenic proteins are complex and
controversial. The morphology of AßP oligomers treated with Al, Cu, Fe, and Zn were reported
to be quite different. Zatta and his colleagues demonstrated that metals including Al, Cu, Fe,
Zn differentially alter the oligomerization of AßP and its toxicity. We have shown that Al
enhances the polymerization of AßP(1-40) and forms SDS-stable oligomers in vitro by immu‐
noblotting and precipitation [15,16]. The oligomerized AßP(1-40) is heat- or SDS-stable but re-
dissolves on adding deferoxamine, a chelator of Al. The oligomerization induced by Al is more
marked than that induced by other metals, including Zn, Fe, Cu, and Cd. Furthermore, while
Zn-aggregated AßPs are rarely observed on the surface of cultured neurons several days after
its exposure, Al-aggregated AßPs bind tightly to the surface of cultured neurons and form
fibrillar deposits. These results suggest that Al-induced AßP oligomers have a strong affinity
to membrane surfaces and undergo minimal degradation by proteases compared to Zn-
induced oligomers. Furthermore, AßP coupled with Al was reported to be highly toxic
compared to normal AßP.
Considering the implications of metals in AD pathogenesis, chelation therapy for AD treat‐
ment is of great interest. Clioquinol (quinoform), a chelator of Cu2+ or Zn2+, inhibits oligome‐
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rization of AßP and attenuates the accumulation of amyloid in the brains of experimental
animals. Clinical trials using its analogue PBT2 are under investigation. DFO, a chelator of Al
and Fe, attenuates the decline of daily living skills in AD patients. Silicates, which couple with
Al and reduce its toxicity, are also candidates for chelation therapy in AD [17].
2.2. Oligomerization-induced neurotoxicity of AßP
There is a considerable interest regarding the mechanisms by which AßP oligomers cause
neurotoxicity. Exposure to AßP causes various adverse effects on neuronal survivals such as
the production of reactive oxygen species, the induction of cytokines, the induction of
endoplasmic reticulum (ER) stresses, and the abnormal increase of intracellular calcium levels
([Ca2+]i), etc [18]. Although these effects may be interwoven, the disruption of Ca2+ homeostasis
is regarded to be an important determinant considering it occurs upstream of the other effects
[19,20]. Ca2+ ions are essential for the normal brain functions. They are involved with key
enzymes such as kinases, phosphatases, and proteases. Therefore, its influx is severely
controlled, and the intracellular Ca2+ levels ([Ca2+]i) are strictly conserved by Ca2+ channels,
etc. Ca2+ is also implicated in the phosphorylation of the tau protein or in APP sequestration.
Increasing evidence indicates that presenilins are involved in capacitative Ca2+ entry or
endoplasmic reticulum (ER) Ca2+ signaling, and that their mutations affect Ca2+-regulated
functions including AßP production [21].
There is considerable interest regarding the mechanism by which AßPs interact with neurons
and disrupt Ca2+ homeostasis. In 1993, Arispe et al. first demonstrated that AßP(1–40) directly
incorporates into artificial lipid bilayer membranes and forms cation-selective ion channels
[22]. The channels termed “amyloid channels” were revealed to be giant multi-level pores and
can allow a large amount of Ca2+ to pass through. Their activity was blocked by Zn2+ ions, which
are abundantly present in the brain. Furthermore, soluble AßP oligomers but not amyloid
fibrils were reported to increase the membrane permeability. Durell et al. proposed a 3-D
structural model of the amyloid channels obtained from a computer simulation of the secon‐
dary structure of AßP(1–40) in membranes that showed 5- to 8-mers aggregating to form pore-
like structures on the membranes. The multimeric (tetramer to hexamer) pore-like structures
of AßPs on reconstituted membranes were observed using atomic force microscopy. Jang et
al. established a model of amyloid channels on the membranes and observed that pentamer
AßPs form pores, and their dimensions, shapes, and subunit organizations are in good
agreement with AFM studies [23]. These results strongly support the hypothetical idea termed
“amyloid channel hypothesis”, which suggests that the direct incorporation of AßPs and the
subsequent imbalances of Ca2+ and other ions through amyloid channels might be the primary
event in AßP neurotoxicity. In this respect, AßP might share the mechanism of toxicity with a
similar mechanism underlying the toxicity of various antimicrobial or antifungal peptides that
also exhibit channel-forming activity and cell toxicity.
To determine whether AßPs form channels on neuronal cell membranes as well as artificial
lipid bilayers, we employed membrane patches from a neuroblastoma cell line (GT1-7 cells),
which exhibit several neuronal characteristics such as the extension of neuritis and the
expression of neuron-specific proteins or receptors [24]. After exposing the excised membrane
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patches of GT1-7 cells in the bath solution to AßP(1–40), the current derived from the amyloid
channels appeared. The amyloid channels formed on the GT1-7 cell membranes were cation-
selective, multilevel, voltage-independent, long-lasting ones; the channel activity was inhib‐
ited by the addition of Zn2+, and recovered by a zinc chelator, o-phenanthroline [25]. These
features were considerably similar to those observed on artificial lipid bilayers. Meanwhile,
AßP(40–1), a peptide bearing the reversed sequence of AßP(1–40), did not form any channels.
Thus, we can conclude that AßPs are directly incorporated into neuronal membranes to form
calcium-permeable pores. In order to test the amyloid channel hypothesis, we examined
whether AßP altered the [Ca2+]i levels in neurons by a high-resolution multi-site video imaging
system with fura-2 as the cytosolic free calcium reporter fluorescent probe. This multisite
fluorometry system enables the simultaneous long-term observation of temporal changes in
[Ca2+]i of more than 50 neurons. We could observe AßP-induced abnormal increase in [Ca2+]i
in GT1-7 cells [26-28] as well as in primary cultured rat hippocampal neurons [29]. Shortly
after exposure to AßP (1–40), a marked increase in [Ca2+]i occurred among many, but not all
neurons. We also observed apoptotic death of cultured neurons after the exposure to AßPs
and the consequent rise in the [Ca2+]i levels.
Considering the results of our study together with those of the other studies, we propose the
following hypothetical scheme of neurodegeneration induced by oligomerization of AßP (Fig.
4).
AßPs are normally secreted from APP into the cerebrospinal fluid and are usually degraded
proteolytically by neprilysin within a short period. However, upregulation of the AßP
secretion from APP, or an increased ratio of AßP(1–42) to AßP(1–40) may render AßPs liable
to be retained in the brain. It has been demonstrated that APP or presenilin gene mutations
promote this process. AßP possesses positive charges at neutral pH. Therefore, the net charge
of the outer membrane surface may be a determinant when secreted AßPs bind to cellular
membranes (Fig.4 (A)). The distribution of phospholipids on cellular membranes is usually
asymmetrical and negatively charged phospholipids such as PS exist on the inner membrane
surfaces. Disruption of the assymetrical distribution is the first hallmark of apoptotic cell death
[30]. Therefore, the binding of AßP to neuronal membranes seldom occur in normal and young
brains. This idea may explain why AD occurs in aged subjects meanwhile AßPs are secreted
in the brains of young subjects. After incorporation into the membrane, the conformation of
AßPs change and the accumulated AßPs aggregate on the membranes (Fig. 4(B)). The ratio of
cholesterol to phospholipids in the membrane may alter membrane fluidity, thereby affecting
the process from step (A) to (B). AßP oligomerization in vitro will also enhance the channel
formation velocity. Considering that natural oligomers (dimers or trimers) are more toxic as
compared to monomers or fibrils, it is provable that these oligomers might form tetrameric or
hexameric pores and exhibit neurotoxicity. Micro-circumstances on the membranes, such as
rafts, are suitable locations that facilitate this process. Finally, aggregated AßP oligomers form
ion channels (Fig.4 (C)) leading to the various neurodegenerative processes. The processes
required for channel formation (from steps (A) to (C)) may require a long life span and
determine the rate of the entire process. Unlike endogenous Ca2+ channels, these AßP channels
are not regulated by usual blockers. Thus, once formed on membranes, a continuous flow of
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[Ca2+]i is initiated. However, zinc ions (Zn2+), which are secreted into synaptic clefts in a
neuronal activity-dependent manner, inhibit AßP-induced Ca2+ entry, and thus have a
protective function in AD.
Once AßP channels are formed on neuronal membranes, homeostasis of Ca2+ and other-ion
will be disrupted. Disruption of Ca2+ homeostasis triggers several apoptotic pathways such as
the activation of calpain, the induction of caspase, and promote numerous degenerative
processes, including the production of reactive oxygen species (ROS) and the phosphorylation
of tau, thereby accelerating neuronal death. Mutations of presenilins cause disturbances in the
capacitive Ca2+ entry and may influence these pathways. Free radicals also induce membrane
disruption, by which unregulated Ca2+ influx is further amplified. The disruption of Ca2+
homeostasis also influences the production and processing of APP. Thus, a vicious cycle of
neurodegeneration is initiated. This hypothesis explains the long delay in AD development;
AD occurs only in senile subjects despite the fact that Aßs are normally secreted also in younger
or in normal subjects. Various environmental factors, such as foods or trace metals, as well as
genetic factors will influence these processes and contribute to AD pathogenesis [31].
3. Prion diseases and other amyloidosis
The disease-related amyloidogenic proteins exhibit similarities in the formation of ß-pleated
sheet structures, abnormal deposition as amyloid fibrils in the tissues, and introduction of
apoptotic degeneration. Prion diseases, including human kuru, Creutzfeldt-Jakob disease, and
bovine spongiform encephalopathy (BSE), are associated with the conversion of a normal prion
protein (PrPC) to an abnormal scrapie isoform (PrPSC) [32]. The ß-sheet region of PrPSC is
suggested to play a crucial role in its transmissible degenerative processes. A peptide fragment
of PrP corresponding to residues 106–126 (PrP106–126) has been reported to cause death in
cultured hippocampal neurons. We investigated the oligomerization of PrP106-126 and its
neurotoxicity on primary cultured rat hippocampal neurons [33]. As AßP, PrP106-126 formed
amyloid-like fibrils with ß–sheet structures by observation with atomic force microspope and
by thioflavin T staining during the aging process. The oligomerization and formation ß-sheet
structure enhanced the neurotoxicity of PrP106-126. The co-existence of Zn or Cu inhibited ß-
sheet formation of PrP106-126 and attenuated its neurotoxicity. Furthermore, the thickness of
PrP106-126 fibrils was decreased in the presence of Zn or Cu.
Electrophysiological and morphological studies have revealed that PrP106-126 exhibits
similarities in the formation of amyloid channels as well as AßP [34]. Lin et al. reported that
PrP106–126 forms cation-permeable pores in artificial lipid bilayers. The activity of PrP
channels was also blocked by Zn2+. Kourie et al. investigated the detailed characteristics of
channels formed by PrP106–126, concluding that it was directly incorporated into lipid bilayers
and formed cation-selective, copper-sensitive ion channels. They also revealed that quinacrine,
a potent therapeutic drug, possibly blocks amyloid channels induced by PrP106-126.
The oligomerization and fibrillation of α-synuclein has been implicated in the formation of
abnormal inclusions, termed Lewy bodies, and the etiology of dementia with Lewy bodies
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(DLB). Non-amyloid component (NAC), a fragment peptide of α-synuclein, accumulates in
Alzheimer’s senile plaques and causes apoptotic neuronal death. Lashuel et al. demonstrated
by electron microscope observation that α-synuclein forms annular pore-like structures [35].
The elongation of a polyglutamine-coding CAG triplet repeat in the responsible genes is based
on the pathogenesis of triplet-repeat disease such as Huntington’s disease or Machado-Joseph
disease. Hirakura et al. reported that polyglutamine formed ion channels in lipid bilayers.
Lal et al. investigated the oligomerization and conformational changes of AßP, synuclein,
amylin, and other amyloidogenic proteins using gel electrophoresis and AFM imaging, and
demonstrated that these amyloidogenic proteins form annular channel-like structures on
bilayer membranes [36]. We have demonstrated that these amyloidogenic peptide also cause
the elevations in [Ca2+]i as well as AßP [3,31]. Considering these results together as shown in
Table 1, it is suggested that the oligomerization of disease-related amyloidogenic proteins and
the introduction of apoptotic degeneration by disruption of calcium homeostasis via unregu‐
lated amyloid channels may be the molecular basis of neurotoxicity of these diseases.
4. Conclusion
This hypothesis about the pathogenesis of conformational diseases may help in the develop‐
ment of drugs for these diseases. We focus carnosine (ß-alanyl histidine) as such a protective
drug. Carnosine is a naturally occurring dipeptide and is commonly present in vertebrate
tissues, particularly within the skeletal muscles and nervous tissues [37]. It is found at high
concentrations in the muscles of animals or fish which exhibit high levels of exercise, such as
horses, chickens, and whales. Thus, it is believed that carnosine plays important roles in the
buffering capacities of muscle tissue and the administration of carnosine has been reported to
induce hyperactivity in animals.
Secretion from synapses of AßP, and its direct incorporation into membranes and formation
of oligomeric amyloid channels are depicted. Details are discussed in the text.
In the brain, a considerable amount of carnosine is localized in the neurons of the olfactory
bulb. It is secreted into synaptic clefts along with the excitatory neurotransmitter glutamate
during neuronal excitation. Carnosine reportedly has several beneficial effects including the
antioxidant activity, the chelating ability to metal ions, the inhibition of the Maillard reaction.
Furthermore, carnosine is reported to have anti-crosslinking properties. Attanasio et al.
reported that carnosine inhibited the fibrillation of alpha-crystallin. It was also demonstrated
that carnosine inhibited the oligomerization and subsequent neurotoxicity of AßP. Corona et
al. showed that dietary supplementation of carnosine attenuated mitochondrial dysfunction
and the accumulation of AßP in Alzheimer’s model mice [38]. We also showed that carnosine
attenuated the neuronal death induced by prion protein fragment peptide (PrP106-126) by
changing its conformation [33]. Carnosine level is significantly reduced in the serum of AD
patients. These results suggest possible beneficial effects of carnosine as a treatment for AD
and prion diseases. We also demonstrated that carnosine attenuates Zn-induced neuronal
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death and becomes a candidate for drugs of vascular dementia [39,40]. All of these functions
of carnosine (e.g., antioxidant, anti-glycating, anti-crosslinking, and scavenging toxic alde‐
hydes) are related to the aging processes. The level of carnosine varies during development
and is low in the aged animals. Therefore, it is highly possible that carnosine protects against
Senile plaque
monomer Oligomer
Ca2+Zn2+
Zn2+
APP
AßP 
PC PS
cholesterol
Disruption of Ca homeostasis
Degeneration of synapses
synapse
Alzheimer’ s disease
▪ Free radical formation
▪ phosphorylation of tau etc.
Neuronal death
ApoE
Foods
Membrane 
composition 
(fluidity, charge)
Neurosteroids
Estradiol
Carnosine
Metals
Figure 4. Amyloid channel hypothesis
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external toxins and acts as an endogenous protective substance against neuronal injury,
senescence, and aging. We have applied patents for carnosine and related compounds as drugs
for vascular type of senile dementia (Patent No. 5382633, Patent No. JP5294194).
In conclusion, further research into the role of protein oligomerization and Ca homeostasis via
amyloid channels might lead to the development of new treatments for neurodegenerative
diseases.
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